Rapport Therapeutics, Inc. · NASDAQ:RAPP
Ceesay Abraham sold 2,210 Rapport Therapeutics, Inc. shares (Form 4)
Traded Sep 23, 2026 · Filed Sep 24, 2026
On Sep 23, 2026, Ceesay Abraham (Director, Chief Executive Officer) sold 2,210 Rapport Therapeutics, Inc. shares at an average US$39.17 for US$86,561 under a trading plan, leaving 456,767 shares. Filed Sep 24, 2026 (Form 4).
- Sold
- 2,210 shares
- Price
- US$39.17 average (US$39.05 to US$41.05)
- Value
- US$86,561
- Holding after
- 456,767 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director, Chief Executive Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Sep 23, 2026 | Common Stock | Sale | 1,952 | US$39.05 | 457,025 | Direct |
| Sep 23, 2026 | Common Stock | Sale | 215 | US$39.86 | 456,810 | Direct |
| Sep 23, 2026 | Common Stock | Sale | 43 | US$41.05 | 456,767 | Direct |
Source
Related
- Rapport Therapeutics, Inc.
- Ceesay Abraham
- Rapport Therapeutics, Inc. shareholders
- Form 4 · Ceesay Abraham · Oct 8, 2026
- Form 4 · Ceesay Abraham · Sep 9, 2026
- Form 4 · Ceesay Abraham · Aug 26, 2026
- Form 4 · Ceesay Abraham · Aug 12, 2026
- Form 4 · Ceesay Abraham · Jul 29, 2026
- Form 4 · Gault Cheryl · Oct 1, 2026
- Form 4 · Yeleswaram Krishnaswamy · Aug 26, 2026
- Form 4 · Yeleswaram Krishnaswamy · Aug 20, 2026
- Schedule 13G/A · Cormorant Asset Management, LP · Aug 14, 2026
- Schedule 13G/A · Third Rock Ventures V, L.P. · Aug 14, 2026